Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1052 participants.

Also called NCT06061692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,052 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06061692
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06061692. Randomized; quadruple masking; primary purpose treatment. Start 2023-10 (anticipated); primary completion 2026-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD)
Condition
Cerebral Small Vessel Diseases
Intervention (Drug)
Tongxinluo Capsule
Lead sponsor
Fudan University (class: other)

Record details

Record id
cardio:ct-nct06061692
Content hash
4c5b47af548cdc9efb1e0f08b54afb7138f199ede906a70b9841535a5c2f9861